ProKidney (PROK)

Chronic kidney disease is a major global health burden and can eventually lead to dialysis, kidney transplantation or severe cardiovascular complications. Diabetic kidney disease is one of the most common causes of advanced kidney failure. ProKidney’s approach is intended to address the underlying decline in kidney function rather than simply manage symptoms or related risk factors.

REACT is manufactured from kidney tissue obtained from the individual patient. Selected renal cells are expanded and prepared for reintroduction into the kidney, where the therapy is intended to support repair or stabilization of kidney function. Because the therapy is autologous, it is based on the patient’s own cells rather than donor-derived or off-the-shelf material.

The company’s pipeline is centered on advancing REACT through clinical development for severe diabetic kidney disease. As with other biotechnology businesses at this stage, ProKidney’s value depends heavily on clinical trial results, manufacturing execution, regulatory review and the ability to demonstrate a meaningful benefit over current standards of care. The company occupies a distinctive niche within kidney therapeutics, combining regenerative medicine, cell processing and nephrology in a field where treatment options remain limited for patients approaching kidney failure.